Pharmaceuticals

Craig Tuman: Silencing the Distractions

bexib
By bexib 0 Min Read

Silence Therapeutics CEO Craig Tooman discusses navigating the rough waters of post-pandemic biotech fundraising and investment, and how a restructured organizational approach has put the company in a stronger position in the growing field of gene silencing with siRNA drugs.

You Might Also Like

NHS cuts long waiting times for cancer treatment and delivers faster ambulance response

Pharma Pulse 5/10/24: Medicare Advantage, Increased Speed ​​with Competition, Global Strategic Business Report for Anti-Obesity Drugs, and More

Novartis plans to acquire Mariana Oncology to strengthen radioligand therapy pipeline

FDA Grants Emergency Use Authorization for Roche’s Cobas Riat SARS-CoV-2, Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Tests

Improving the U.S. supply chain to improve patient outcomes

Share This Article
Previous Article How to Verify Domain Name Ownership with WHOIS (2024)
Next Article After a moist spring, many areas are expected to experience dry weather through the summer – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

China’s seapower expands as US shipyards decline
Manufacturing
Print advertising is an e-commerce opportunity
Retail & E-commerce
Top 6 banking trends to grow across Asia in 2025
Fintech
The Difference Between Direct Carrier Appointments and Producer Sub-Codes
Insurance